More than 6,000 members have joined the Biologic Association within the first six months of its website launch.

Since the beginning of the year, Becker's Spine Review has reported on eight orthobiologic and regenerative medicine companies that have launched new products, received FDA clearances and demonstrated favorable outcomes in clinical trials:

Orthobiologics company Cerapedics received FDA approval to reduce the number of patients required for its P-15L bone graft clinical trial.

Spinal implant developer Spine Wave has launched its Tempest Allograft Bone Matrix, according to a July 14 news release.

Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant. 

Orthobiologics company Baxter has received FDA clearance July 9 for its Altapore Shape Bioactive Bone Graft for spine surgery, according to Biospace.

Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.

Orthobiologics company Bioventus on June 25 launched its Signafuse bioactive bone graft in a strip format.

Here are four key developments in spinal biologics in the last month:

Biomaterials startup Spiderwort has closed a $3.4 million seed financing round one year after it secured $500,000 in a friends and family funding round, Betakit reports.

Minimally invasive spine therapy company SpineOvations reported favorable results at the midpoint of its DiscSeal clinical trial.

The European Commission recently approved Zolgensma, Novartis' $2.1 million gene therapy drug for spinal muscular atrophy, for infants and children up to 46 pounds.

Orthobiologics company Cerapedics published data from a clinical trial examining the fusion rate of its i-Factor bone graft in noninstrumented lumbar fusion.

The FDA on May 4 granted biotechnology company Alume Biosciences permission to investigate the use of a nerve imaging drug during spine surgery, Biospace reports.

The FDA granted Carmell Therapeutics Fast Track designation on April 27 for its debut product, a bone healing accelerant, OA Online reports.

Stefanos Theoharis, PhD, was appointed chief business officer of Bone Therapeutics on March 26.

Zolgensma, Novartis' gene therapy drug for spinal muscular atrophy, recently demonstrated significant therapeutic benefits for patients in various extended clinical trials, reports Pharmaceutical Technology.

The Japanese Ministry of Health, Labour and Welfare recently approved Zolgensma, Novartis' gene therapy drug for the treatment of spinal muscular atrophy, for infants under the age of 2, according to Medical Dialogues.

Regenerative medicine therapies hold much potential in the orthopedic space, despite the lack of comprehensive knowledge around the therapies. Here, Anika Therapeutics interim CEO Cheryl Blanchard, PhD, explains how the company plans to approach the biologics market.

SpineOvations on Feb 24. finished enrollment for its DiscSeal clinical study in patients suffering from lumbar pain.